Shares of Zogenix (ZGNX) fell 45% after a Food and Drug Administration advisory committee reviewing its extended-release painkiller Zohydro voted 11-2 against the drug. Much of the resistance from the committee focused on potential abuse of the drug, and Zohydro in its current form is not crush-resistant. In this video, Motley Fool health care bureau chief Brenton Flynn tells us why this is such a devastating blow for the company, and what, if anything, in Zogenix's pipeline may save it.